Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort - Scorecard - MDSpire
Advertisement
Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort
Clinical Scorecard: Evaluating the Role of Histological Remission in Predicting Clinical Relapse Among Crohn’s Disease Patients: Insights from the STORI Cohort Analysis
At a Glance
Category
Detail
Condition
Crohn’s disease (CD)
Key Mechanisms
Histological inflammation and its potential role in predicting clinical relapse; correlation with endoscopic scores and biomarkers
Target Population
Patients with Crohn’s disease in clinical remission treated with infliximab and immunosuppressors
Care Setting
Multicenter gastroenterology clinics with endoscopic and histological assessment capabilities
Key Highlights
Histological remission rates varied between 41% and 61% depending on scoring system used (Nancy, Robarts, Geboes, IBD-DCA).
Histological scores did not predict clinical relapse in Crohn’s disease patients in remission.
Fecal calprotectin was the only significant predictor of clinical relapse in multivariate analysis.
Guideline-Based Recommendations
Diagnosis
Use ileocolonoscopy with Crohn’s Disease Endoscopic Index of Severity (CDEIS) for endoscopic assessment.
Obtain biopsies from most inflamed or previously inflamed areas for histological scoring.
Management
Focus on achieving mucosal healing and normalization of biomarkers as primary treatment goals.
Histological remission is not currently recommended as a clinical target for predicting relapse risk in CD.
Monitoring & Follow-up
Monitor clinical relapse using Crohn’s Disease Activity Index (CDAI) criteria.
Use fecal calprotectin levels (<300 µg/L threshold) as a significant biomarker to predict relapse risk.
Risks
Histological inflammation does not reliably predict clinical relapse, thus reliance on histology alone may misinform risk assessment.
Patient & Prescribing Data
Crohn’s disease patients in stable remission on combined therapy with infliximab and immunosuppressors
Discontinuation of infliximab assessed in STORI cohort; histological remission status did not influence relapse rates, highlighting limited utility of histology in guiding therapy adjustments.
Clinical Best Practices
Prioritize endoscopic and biomarker (fecal calprotectin, hsCRP) assessments over histological scores for relapse risk evaluation.
Standardize biopsy location to most or previously inflamed areas for consistent histological evaluation.
Use central reading by experienced pathologists to ensure histological scoring reliability in research settings.
Consider histological remission as a research endpoint rather than a routine clinical target in Crohn’s disease management.
